HG004

Phase 2Small molecule

HHuidaGene Therapeutics Co., Ltd.

HG004 is one of 4 small molecule programs targeting Leber Congenital Amaurosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leber Congenital AmaurosisRecruiting

Leber Congenital AmaurosisPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Leber Congenital Amaurosis

#DrugCompanyPhaseTrials

AAV2-Hrpe65v2,voretigene Neparvovec-Rzyl

SSpark Therapeutics, Inc.

Phase 3

1 2

Rayos

RRoxane Laboratories

Preclinical

1 3

Voretigene Neparvovec-Rzyl

SSpark Therapeutics, Inc.

Phase 2

2 4

HG004

HHuidaGene Therapeutics Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leber Congenital Amaurosis1 trial

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

Recruiting·HHuidaGene Therapeutics Co., Ltd.·Phase 1/2·NCT05906953·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HG004. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HG004 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HG004. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HuidaGene Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHuidaGene Therapeutics Co., Ltd.

HG004

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leber Congenital Amaurosis1 trial

References

Drug Info

Quick Facts

Related News